SOFOSBUVIR/VELPATASVIR FIXED-DOSE COMBINATION AND RIBAVIRIN FOR 12 OR 24 WEEKS IN PARTICIPANTS WITH CHRONIC GENOTYPE 1 OR 2 HEPATITIS C VIRUS INFECTION WHO HAVE PREVIOUSLY FAILED A DIRECT-ACTING ANTIVIRAL-CONTAINING REGIMEN: